Get the Stockscreener App
4.99
4.18%
0.20
After Hours:
4.85
-0.14
-2.81%
Rezolute Inc stock is traded at $4.99, with a volume of 404.57K.
It is up +4.18% in the last 24 hours and down -13.67% over the past month.
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
See More
Previous Close:
$4.79
Open:
$4.81
24h Volume:
404.57K
Relative Volume:
1.03
Market Cap:
$277.55M
Revenue:
-
Net Income/Loss:
$-68.46M
P/E Ratio:
-4.99
EPS:
-1
Net Cash Flow:
$-57.37M
1W Performance:
-0.40%
1M Performance:
-13.67%
6M Performance:
+40.17%
1Y Performance:
+544.04%
1-Day Range:
$4.70
$5.05
1-Week Range:
$4.68
$5.14
52-Week Range:
$0.72
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.99 | 277.55M | 0 | -68.46M | -57.37M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks
BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN
Wedbush Initiates Coverage of Rezolute (RZLT) with Outperform Recommendation - MSN
(RZLT) On The My Stocks Page - Stock Traders Daily
Institutional investors in Rezolute, Inc. (NASDAQ:RZLT) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Rezolute's SWOT analysis: biotech stock eyes growth amid clinical progress - Investing.com India
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully - Yahoo Finance
Rezolute stock soars to 52-week high, hits $6.1 amid surge By Investing.com - Investing.com South Africa
Rezolute stock soars to 52-week high, hits $6.1 amid surge - Investing.com India
(RZLT) Investment Report - Stock Traders Daily
Rezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC Wainwright - MarketBeat
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update - The Manila Times
Rezolute Advances Phase 3 Trials Despite $15.4M Loss; Maintains $117.8M Cash Position | RZLT Stock News - StockTitan
Equities Analysts Offer Predictions for Rezolute Q1 Earnings - MarketBeat
Wedbush Reaffirms “Outperform” Rating for Rezolute (NASDAQ:RZLT) - Defense World
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
Rezolute (NASDAQ:RZLT) Given Outperform Rating at Wedbush - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives $11.57 Consensus Target Price from Analysts - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Receives $11.57 Average Price Target from Brokerages - MarketBeat
(RZLT) Technical Pivots with Risk Controls - Stock Traders Daily
SEC Form DEFA14A filed by Rezolute Inc. - Quantisnow
AAO 2024: Rezolute’s RZ-402 shows promising Phase IIa results in DME patients - Yahoo Finance
With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing - Yahoo Finance
Cubist Systematic Strategies LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Renaissance Technologies LLC Sells 149,660 Shares of Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Marshall Wace LLP Invests $4.50 Million in Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
Continuing Rare Disease Treatment With A Compassionate Use Program (CUP) - Clinical Leader
Nantahala Capital Management LLC Cuts Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
XTX Topco Ltd Has $145,000 Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute's SWOT analysis: biotech firm's stock poised for growth amid clinical trials - Investing.com
Rezolute, Inc. (NASDAQ:RZLT) Short Interest Update - MarketBeat
Rezolute (NASDAQ:RZLT) Receives Buy Rating from HC Wainwright - MarketBeat
Rezolute Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Rezolute Inc [RZLT] stock for 20,017 USD was acquired by Hogenhuis Wladimir - Knox Daily
Director Wladimir Hogenhuis Acquires 4,259 Shares of Rezolute In - GuruFocus.com
Affinity Asset Advisors LLC Acquires 250,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Affinity Asset Advisors LLC Purchases 250,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
Rezolute executive Wladimir Hogenhuis buys $20,017 in company stock By Investing.com - Investing.com Australia
Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Buys 4,259 Shares - Defense World
Rezolute executive Wladimir Hogenhuis buys $20,017 in company stock - Investing.com
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - MSN
BTIG bullish on Rezolute stock as pivotal trials move forward and hold lifted - Investing.com Canada
Rezolute Inc [RZLT] Director makes an insider acquire of 4,815 shares worth 19,982. - Knox Daily
Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS - Defense World
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rezolute Inc Stock (RZLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Jun 25 '24 |
Buy |
4.15 |
4,815 |
19,982 |
37,508 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
4,300 |
16,828 |
54,352 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
3,300 |
12,916 |
13,000 |
| Evans Daron | CFO |
Jun 14 '24 |
Buy |
4.04 |
40,000 |
161,568 |
40,000 |
| Evans Daron | CFO |
May 29 '24 |
Buy |
3.50 |
451 |
1,578 |
121,351 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
May 23 '24 |
Buy |
2.69 |
7,500 |
20,138 |
50,052 |
| Evans Daron | CFO |
May 24 '24 |
Buy |
3.23 |
2,942 |
9,503 |
13,000 |
| Evans Daron | CFO |
May 23 '24 |
Buy |
2.85 |
58 |
165 |
10,058 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Mar 28 '24 |
Buy |
2.55 |
500 |
1,275 |
1,076 |
| Evans Daron | CFO |
Mar 15 '24 |
Buy |
1.69 |
20,000 |
33,830 |
20,000 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):